TCT 2020 | Surprising Differences in Stroke between SAPIEN 3 and Evolut R

One-year outcomes of the head to head trial between CoreValve Evolut R vs Sapien 3 showed a significantly higher difference in stroke vs. patients receiving the self-expanding valve (Sapien 3 6.9% vs Evolut R 1%; p=0.002).

The SOLVE-TAVI randomized 2×2 patients with severe aortic stenosis and high surgical risk to Sapien 3 or Evolut R and general anesthesia or conscious sedation. 

Both devices resulted comparable for the combined end point of death, stroke, moderate to severe aortic regurgitation and the need of new definite pacemaker

The difference in stroke is surprising and difficult to explain since the number observed in this study for the Sapien 3 greatly exceeds the one observed in other studies, such as the SOURCE 3 and the PARTNER 3, which had used the same device. 

Between 30 days and one year there were no significant differences in stroke, therefore they were peri-procedural strokes. 


Read also: TCT 2020 | Fewer Symptoms and Events when Optimizing with iFR.


All-cause mortality resulted practically identical (17.6% with Evolut R vs 17.0% with Sapien 3; p=0.88), moderate to severe aortic regurgitation rate favored the Sapien 3 numerically, but not significantly (7.0% with Evolut R vs 4.5% with Sapien 3; p=0.35).

Definite pacemaker rate was relatively high and similar between devices (24.7% with Evolut R vs 20.2% with Sapien 3; p=0.25).

As regards the comparison between conscious sedation and general anesthesia, mortality, stroke, MI, infection, and kidney injury rates were equivalent between strategies. 


Read also: TCT 2020 | The Myth of Biodegradable Polymers Seems to Have Come to an End.


Conscious sedation saw shorter intensive care unit stay and shorter total hospital stay. A cost analysis that should favor conscious sedation is expected. 

Original Title: SOLVE-TAVI investigators. A 2 x 2 randomized trial of self-expandable vs balloon-expandable valves and general vs local anesthesia in patients undergoing transcatheter aortic valve implantation: 1-year result.

Reference: presentado por Feistritzer H-J en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

IVUS Assessment in Patients at High Risk of Coronary Occlusion After TAVI: Results from the ICARO Study

Courtesy of Dr. Juan Manuel Pérez. Acute coronary obstruction (ACO) is a rare but potentially fatal complication following transcatheter aortic valve implantation (TAVI), particularly in...

Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing...

Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes

Tricuspid regurgitation (TR) has been associated with increased mortality and functional deterioration. Even though the current guidelines recommend tricuspid valve surgery, supporting evidence is...

EuroPCR 2025 | TRI-SCORE for Predicting Mortality After Tricuspid Valve TEER: The EURO TR Registry

Researchers analyzed a total of 1062 patients who underwent transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation (TR). Risk was classified using the TRI-SCORE: low (0–3...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Watchman FLX and Improvement Impact vs. 2.5

Left atrial appendage occlusion (LAAO) represents an effective alternative to oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation at high risk of thromboembolic...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...